Papivax Biotech Incorporated

PapiVax Biotech, Inc. is a biotechnology company developing immunotherapy treatments for chronic HPV infection and HPV-related cancers, with Phase II clinical assets utilizing self-adjuvanting DNA vaccines. The company focuses on preventing and treating cancers caused by human papillomavirus, which is linked to cervical cancer, head and neck cancer, anal cancer, and other genital malignancies.